首页> 外文OA文献 >Treatment with Etanercept in a Patient with Rheumatoid Arthritis-Associated Interstitial Lung Disease
【2h】

Treatment with Etanercept in a Patient with Rheumatoid Arthritis-Associated Interstitial Lung Disease

机译:类风湿关节炎相关性间质性肺疾病患者的依那西普治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We report a case of a 52-year-old woman with a 1-year history of rheumatoid arthritis-associated interstitial lung disease referred to hospital because of aggravated pulmonary symptoms in spite of intensive treatment including prednisone, azathioprine and triptergium glycoside. We subsequently initiated treatment with 25 mg of etanercept, subcutaneously injected twice weekly. Following 6 months of therapy with this agent, sustained improvement in dyspnea, cough was reported by the patient and respiratory function test showed marked improvement. The improvement was confirmed by reduced middle and lower lung markings on chest radiography and high-resolution CT scan. This report suggests etanercept may be effective in the treatment of rheumatoid arthritis-associated interstitial lung disease.
机译:我们报告了一例52岁的妇女,尽管接受了强的松,硫唑嘌呤和雷公藤多甙的强化治疗,但由于肺部症状加重,而有1年的类风湿关节炎相关性间质性肺病病史,但仍转诊至医院。随后我们开始用25 mg依那西普治疗,每周两次皮下注射。用该药治疗6个月后,呼吸困难持续改善,患者报告咳嗽,呼吸功能测试显示明显改善。胸部X线检查和高分辨率CT扫描减少了中,下肺部标记,证实了这种改善。该报告表明依那西普可能在类风湿关节炎相关的间质性肺疾病的治疗中有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号